AP Biosciences Inc (TPEX:6945)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
180.00
+8.00 (4.65%)
Dec 31, 2025, 2:59 PM CST
262.54%
Market Cap15.32B
Revenue (ttm)n/a
Net Income (ttm)-447.41M
Shares Out85.11M
EPS (ttm)-5.26
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume590,389
Average Volume1,187,802
Open169.50
Previous Close172.00
Day's Range169.50 - 183.50
52-Week Range36.30 - 197.50
Beta0.33
RSI63.73
Earnings DateMar 20, 2026

About AP Biosciences

AP Biosciences Inc researches and develops protein and antibody drugs for unmet medical needs. It develops IBI302 that is in phase III clinical trials for the treatment of neovascular age-related macular degeneration; AP505 that is in phase I clinical trials for treating solid tumors; AP203 that is in phase I clinical trial for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous-cell carcinomas; AP402, which is in in the pre-clinical research phase for breast cancer patients; and AP601 that is in pre-clini... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 37
Stock Exchange Taipei Exchange
Ticker Symbol 6945
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.